Abstract Gangliogliomas (WHO grade I) are rare tumors affecting the central nervous system and are most frequently observed in children. Next-generation sequencing of tumors is being utilized at an increasing rate in both research and clinical settings to characterize the genetic factors that drive tumorigenesis.
was consistent with a low-grade glioma. The patient did not display other symptoms prior to diagnosis (e.g., gait issues, headaches, motor weakness, vomiting, or seizures). Postoperative follow-up included a physical exam and MRI surveillance imaging every 3-4 months. During this time, imaging demonstrated slow interval growth, but the patient reported no clinical symptoms that were related to the tumor growth (e.g., headaches, vision changes). The patient was referred for chemotherapy but has not yet undergone any therapies. Four years after her initial diagnosis, a surveillance MRI indicated some central enhancement in the midbrain lesions that could represent a cyst; follow-up MRI demonstrated increased diffusion restriction and open biopsy was recommended. A needle biopsy confirmed a diagnosis of ganglioglioma, WHO grade I, and provided the specimen studied by next-generation sequencing (NGS) assays, as described herein.
TECHNICAL ANALYSIS AND METHODS
Whole-Genome and Whole-Exome Sequencing Whole-exome sequencing (WES) and whole-genome sequencing (WGS) were performed on DNA isolated from the tumor biopsy and from peripheral blood (PBMC; i.e., normal comparator). Genomic DNA was processed for WGS using NEBNext Ultra II library prep. WES libraries were captured with the Agilent SureSelect v6 Exome kit (Agilent Technologies). Pairedend 151-bp reads were generated for exome-enriched and WGS libraries sequenced on the Illumina HiSeq 4000. Reads were aligned to the human genome reference sequence, build GRcH37, using Churchill and evaluated (Kelly et al. 2015) . Sequence alignments were refined according to community-accepted guidelines for best practices (https://www. broadinstitute.org/gatk/guide/best-practices). Duplicate sequence reads were removed using samblaster-v.0.1.22, local realignment was performed on the aligned sequence data using the Genome Analysis Toolkit (GATK) (v3.7-0), and Churchill's own deterministic implementation of base quality score recalibration was used. The GATK's HaplotypeCaller was used to call germline variants. Average sequencing coverage depth for the tumor sample was 221× (WES) and 55× (WGS); for the normal sample, coverage was 230× (WES) and 31× (WGS). Somatic single-nucleotide variation (SNV) and indel detection was performed for the WGS and WES data sets separately using MuTect 2 (Cibulskis et al. 2013) . Detection of copy-number variation (CNV), as well as somatic and germline structural variation (SV), was performed using WGS data.
Sanger Sequencing DNA derived from peripheral blood and tumor was independently used as template to PCR amplify BRAF exon 15 using the following primer sequences: exon 15F 5 ′ -GTAAAACGA CGGCCAGACTCTTCATAATGCTTGCTCTGA-3 ′ and exon 15R 5 ′ -CAGGAAACAGCTA TGACAGTAACTCAGCAGCATCTCAGG-3 ′ . The resulting 251-bp products were purified (QIAGEN, 28106) and Sanger sequenced (ThermoFisher, 4336943) using M13 forward and reverse primers. Electropherograms were analyzed using Sequencher version 5.3.
RNA-seq
DNase-treated, ribo-depleted total tumor RNA was used as input for library construction using Illumina's TruSeq Stranded Total RNA Sample prep. RNA-seq data were processed using STAR-Fusion, and these data were used to detect putatively expressed gene fusions in the tumor (https://github.com/STAR-Fusion). We analyzed 125,302,701 RNA-seq reads.
Somatic BRAF c.1794_1796dupTAC;p.Thr599dup in pediatric patient with ganglioglioma
VARIANT INTERPRETATION
SnpEff and custom in-house scripts were used to annotate variants (mutation and gene information), predict their functional impact on proteins, and assign population allele frequencies (Cingolani et al. 2012) . Variants observed in the matched normal sample (i.e., germline) were excluded from somatic analysis. Common variants (MAF > 1%), variants outside of coding regions (>4 bp from an exon splice site), and exonic synonymous variants were also excluded from analysis. Potential variants were screened for cancer relevance based on previous reports in ClinVar, COSMIC, dbSNP, ICGC, and TCGA databases.
RESULTS
After filtering as described above, a total of 15 somatic nonsynonymous variants were further evaluated for cancer relevance. Our somatic analysis detected a pathogenic variant c.1794_1796dupTAC;p.Thr599dup in the BRAF gene ( Table 1 ). The duplication of three nucleotides results in an in-frame introduction of a threonine residue at amino acid 599 (Fig. 1) . Histology reports indicated a 70% tumor cellularity; however, the variant allele frequency (VAF) of somatic mutations suggests a much lower actual tumor cellularity. To return the results to the physician for patient care, clinical confirmation of the variant was performed by amplification of exon 15 of the BRAF gene, followed by bidirectional Sanger sequencing. Our initial confirmation assay was negative, because of low tumor content in the sample and the relative insensitivity of Sanger assays. As such, we identified a second portion of the biopsy specimen with a higher predicted tumor cellularity and isolated DNA for the Sanger confirmation, which indicated the variant was present at a low, but detectable, allelic frequency (Fig. 1) . In parallel, we identified the presence of this variant and expression of the variant allele in RNA-seq data. We discovered a gene fusion transcript TFG-GPR128 in the RNA-seq data, which we determined to be irrelevant because this particular fusion has been identified in multiple healthy individuals (Chase et al. 2010) . WGS analysis did not identify any LOH/CNV regions in the tumor. Other variants (SNVs, indels, SVs) involving cancer genes were not identified in our somatic analyses. Germline WES and WGS analysis did not reveal any pathogenic variants in known cancer predisposition genes (Zhang et al. 2015 ).
SUMMARY
Previous in vitro studies of the p.T599dup variant demonstrated kinase activity and cellular MEK/ERK activation potential comparable to that of BRAF p.V600E, suggesting that a similar therapeutic approach as for V600E may be effective (Eisenhardt et al. 2011) . Presumably, the duplication of the threonine residue destabilizes the inactive conformation of the kinase domain. The c.1794_1796TACdup variant was classified as Tier II, Level C variant in Somatic BRAF c.1794_1796dupTAC;p.Thr599dup in pediatric patient with ganglioglioma
C O L D S P R I N G H A R B O R
Molecular Case Studies accordance with the AMP/ASCO Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer (Li et al. 2017) . The variant has a potential clinical actionability based on reports demonstrating therapeutic and diagnostic/prognostic utility of BRAF p.V600 substitution mutations. Although the c.1794_1796dupTAC somatic variant has been observed in other cancers, notably in thyroid cancer, melanoma, and pilocytic astrocytoma, it has not been previously described in low-grade ganglioglioma (Jones et al. 2009; Yu et al. 2009; Gauchotte et al. 2011; Menzies et al. 2012) . Furthermore, the variant was not identified in germline DNA of more than 15,000 individuals in the gnomAD database (Lek et al. 2016 ).
We describe a somatic in-frame mutation in exon 15 of BRAF in the tumor genome of a pediatric patient with ganglioglioma. The mutation duplicates the threonine residue at amino acid 599. Somatic mutations of BRAF are found with particularly high frequency in melanoma and colorectal, ovarian, and thyroid carcinomas (Davies et al. 2002; Curtin et al. 2005; Murugan et al. 2016) . Specifically, the p.V600E variant accounts for >70% of reported somatic pathogenic mutations in BRAF (Wan et al. 2004; Watson et al. 2013 ). Specific to gangliogliomas, BRAF substitutions are quite common. For example, BRAF p.V600E has been Somatic BRAF c.1794_1796dupTAC;p.Thr599dup in pediatric patient with ganglioglioma
observed in 25%-35% of adult and pediatric gangliogliomas (Schindler et al. 2011; Qaddoumi et al. 2016) , whereas other BRAF genetic alterations and KIAA1549-BRAF and FAM131B-BRAF fusions have also been observed in low-grade gliomas, the former fusion having been identified in gangliogliomas (Dimitriadis et al. 2013; Gupta et al. 2014; Roth et al. 2015) . All of the above BRAF alterations cause increased activation of BRAF and therefore constitutive activation of the mitogen-activated protein kinase (MAPK) pathway. Previous studies have indicated that the c.1794_1796dupTAC mutation described here is pathogenic and mimics the increased oncogenic kinase activity associated with BRAF p.V600E (Eisenhardt et al. 2011) . Inhibitors that can target aberrant BRAF expression (e.g., vemurafenib, dabrafenib) have been shown to positively impact disease outcomes and treatment responses in patients with BRAF V600 substitutions (Flaherty et al. 2012; Hyman et al. 2015; Karoulia et al. 2017) . Specific therapeutic agents based on our patient's oncogenotype are currently being pursued.
Beyond tumor resection, radiation therapy, or chemotherapy, which often directly lead to comorbidities and/or adverse events, it is anticipated that this type of targeted therapy offers an alternative treatment strategy for this patient. It is exciting and encouraging to think about translating knowledge of somatic mutations into effective therapeutic agents, as the neurooncology community continues to reveal the molecular landscape of rare, pediatric brain tumors.
In conclusion, we suggest that screening for somatic BRAF alterations should extend beyond the well-documented hotspot variant BRAF p.V600E, as the pathogenic variant p.T599dup described here mimics the increased oncogenic kinase activity associated with p.V600E (Eisenhardt et al. 2011) . It is critical that genetic assays, particularly for BRAF mutations, are capable of detecting a full range of genotypes, as the identification of pathogenic variants can lead to targeted treatment approaches for patients, as discussed here.
ADDITIONAL INFORMATION Database Deposition and Access
The variant has been deposited in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) under accession number SCV000611854.
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